Eli Lilly Expands Oncology and Genetic Medicine Portfolio with $3.25 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is set to acquire Kelonia Therapeutics for $3.25 billion upfront, aiming to strengthen its oncology and genetic medicines pipeline beyond its existing GLP-1 offerings.